Relmada Therapeutics (4E2) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4E2 Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Relmada

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4E2 Stock 12 Month Forecast

Average Price Target

€12.59

▲(118.94% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Relmada Therapeutics in the last 3 months. The average price target is €12.59 with a high forecast of €16.69 and a low forecast of €10.54. The average price target represents a 118.94% change from the last price of €5.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","17":"€17","-1":"-€1","3.5":"€3.5","12.5":"€12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.68773135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.588990316666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.5396198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.54</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.5,8,12.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,6.729825488461539,7.559650976923077,8.389476465384616,9.219301953846154,10.049127442307693,10.87895293076923,11.70877841923077,12.538603907692309,13.368429396153847,14.198254884615386,15.028080373076923,15.857905861538462,{"y":16.68773135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,6.414537716666667,6.929075433333334,7.443613150000001,7.958150866666667,8.472688583333333,8.9872263,9.501764016666668,10.016301733333334,10.53083945,11.045377166666668,11.559914883333335,12.0744526,{"y":12.588990316666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,6.256893830769231,6.613787661538462,6.970681492307692,7.327575323076923,7.684469153846154,8.041362984615386,8.398256815384617,8.755150646153847,9.112044476923078,9.468938307692309,9.82583213846154,10.18272596923077,{"y":10.5396198,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.49,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.525,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.905,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.639,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€16.69

Average Price Target€12.59

Lowest Price Target€10.54

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Uy Ear

Mizuho Securities

€16.69

Buy

190.22%

Upside

Reiterated

07/10/26

Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)

Andres Y. Maldonado

H.C. Wainwright

€10.54

Buy

83.30%

Upside

Reiterated

06/23/26

Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)

Kelsey Goodwin

Piper Sandler

€10.54

Buy

83.30%

Upside

Reiterated

05/13/26

Piper Sandler Sticks to Its Buy Rating for Relmada Therapeutics (RLMD)

Christopher Liu

Lucid Capital

€12.3

Buy

113.85%

Upside

Initiated

03/02/26

Relmada Therapeutics initiated with a Buy at Lucid CapitalRelmada Therapeutics initiated with a Buy at Lucid Capital

Andrew Berens

Leerink Partners

€7.03

Buy

22.20%

Upside

Initiated

01/23/26

Relmada Therapeutics assumed at Outperform from Market Perform at LeerinkRelmada Therapeutics assumed at Outperform from Market Perform at Leerink

Farzin Haque

Jefferies

€7.9

Buy

37.47%

Upside

Initiated

12/21/25

Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (NASDAQ: RLMD) and Telix Pharmaceuticals (Other OTC: TLPPF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Uy Ear

Mizuho Securities

€16.69

Buy

190.22%

Upside

Reiterated

07/10/26

Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)

Andres Y. Maldonado

H.C. Wainwright

€10.54

Buy

83.30%

Upside

Reiterated

06/23/26

Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)

Kelsey Goodwin

Piper Sandler

€10.54

Buy

83.30%

Upside

Reiterated

05/13/26

Piper Sandler Sticks to Its Buy Rating for Relmada Therapeutics (RLMD)

Christopher Liu

Lucid Capital

€12.3

Buy

113.85%

Upside

Initiated

03/02/26

Relmada Therapeutics initiated with a Buy at Lucid CapitalRelmada Therapeutics initiated with a Buy at Lucid Capital

Andrew Berens

Leerink Partners

€7.03

Buy

22.20%

Upside

Initiated

01/23/26

Relmada Therapeutics assumed at Outperform from Market Perform at LeerinkRelmada Therapeutics assumed at Outperform from Market Perform at Leerink

Farzin Haque

Jefferies

€7.9

Buy

37.47%

Upside

Initiated

12/21/25

Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (NASDAQ: RLMD) and Telix Pharmaceuticals (Other OTC: TLPPF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

GKOSGlaukos

ARDXArdelyx

STOKStoke Therapeutics

MIRMMirum Pharmaceuticals

CSTLCastle Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Relmada Therapeutics

3 Months

Uy EarMizuho Securities

Success Rate

8/26 ratings generated profit

Average Return

-17.33%

Copying Uy Ear's trades and holding each position for 3 Months would result in 30.77% of your transactions generating a profit, with an average return of -17.33% per trade.

1 Year

Uy EarMizuho Securities

Success Rate

8/26 ratings generated profit

Average Return

-32.36%

Copying Uy Ear's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -32.36% per trade.

2 Years

Uy EarMizuho Securities

Success Rate

3/26 ratings generated profit

Average Return

-59.66%

Copying Uy Ear's trades and holding each position for 2 Years would result in 11.54% of your transactions generating a profit, with an average return of -59.66% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4E2 Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4E2 has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4E2 average Analyst price target in the past 3 months is 12.59.

Each month's total comprises the sum of three months' worth of ratings.

4E2 Financial Forecast

4E2 Earnings Forecast

Next quarter’s earnings estimate for 4E2 is -€0.18 with a range of -€0.20 to -€0.17. The previous quarter’s EPS was -€0.19. 4E2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 4E2 has Performed in-line its overall industry.

No data currently available

4E2 Sales Forecast

Next quarter’s sales forecast for 4E2 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 4E2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 4E2 has Performed in-line its overall industry.

4E2 Stock Forecast FAQ

What is DE:4E2’s average 12-month price target, according to analysts?

Based on analyst ratings, Relmada Therapeutics Inc’s 12-month average price target is 12.59.

What is DE:4E2’s upside potential, based on the analysts’ average price target?

Relmada Therapeutics Inc has 118.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Relmada Therapeutics Inc a Buy, Sell or Hold?

Relmada Therapeutics Inc has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Relmada Therapeutics Inc’s share price target?

The average share price target for Relmada Therapeutics Inc is 12.59. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €16.69 ,and the lowest forecast is €10.54. The average share price target represents 118.94% Increase from the current price of €5.75.

What do analysts say about Relmada Therapeutics Inc?

Relmada Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Relmada Therapeutics Inc?

To buy shares of DE:4E2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Relmada Therapeutics (4E2) Stock Forecast & Price Target

4E2 Analyst Ratings

4E2 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Relmada Therapeutics

4E2 Analyst Recommendation Trends

4E2 Financial Forecast

4E2 Earnings Forecast

4E2 Sales Forecast

4E2 Stock Forecast FAQ

Detailed List of Analyst Forecasts